In the context of cancer chemotherapy, current study has shown that both p53 and apical kinases ataxia-telangiectasia mutated (ATM) regulate FOXM1 coordinately via E2F1 and consequently modulate epirubicin sensitivity in breast cancer [48], [53]. The gene discussed is FOXM1; the disease is breast carcinoma.